Together we shape the future of HPB

Improving the success​ rate of diagnostic​ procedures​

Celebrating 20 years of Cholangioscopy

Did you know that the SpyGlass™ DS II Direct Visualization System has been adopted in over 85 countries1 and has facilitated more than 250,000 procedures since 20161?

celebrating-spyglass

20 years since FDA Cleared first Single-Operator Cholangioscopy System SpyGlassTM

10 years since FDA Approved first digital Single-Operator Cholangioscopy System SpyGlassTM DS

5 years since FDA Approved SpyGlassTM Discover

The value of direct visualization

spyscope DS II CU

The SpyGlass DS System enables high resolution imaging and therapy during an endoscopic retrograde cholangiopancreatography (ERCP) procedure to target biopsies and fragment stones.2

A 2019 study examined the role of digital cholangiopancreatoscopy technology in mapping the extent of malignant involvement in the biliary or pancreatic ducts before surgical intervention. Through an analysis of 118 patients, it demonstrated that the surgical plan was altered in 34% of cases when using direct visualization with the SpyGlass™ DS System.3

85% altered 

In a clinical study of 298 patients, clinical management was altered in 85% of patients undergoing diagnostic ERCP with Cholangioscopy.4

89% success

Demonstrated 89% stone clearance after a single ERCP session may allow patients to avoid repeat endoscopic interventions or more invasive procedures to treat difficult biliary and pancreatic stones.5

buy

In a study, it was suggested SpyGlass DS could help reduce number of repeat procedures, hence reducing the overall expenditure of hospitals.6

Clinical cases aren't predictive of device performance.

Diagnostic ERCP performed with:​

Fluoroscopic visualization​

Fluoroscopic visualization​

SpyGlass™ DS Direct Visualization System​

SpyGlass™ DS Direct Visualization System​

Find out how direct visualization can help you improve patient outcomes:

View product information for​ the SpyGlass™ DS Direct Vizualisation System:​

SpyGlass™  DS  Direct Vizualisation  System​

The SpyGlassTM Direct Vizualisation System enables direct visualization of the pancreatic and bile ducts. It is used to evaluate suspected benign and malignant conditions and to treat difficult stones and strictures​.

SpyGlass DS II clinical SpyBite

Driving innovation in HPB diagnosis​

At Boston Scientific, we understand the challenges you may face in achieving a diagnosis for your patients. We have developed a suite of solutions to help support them:​

Connect with us:


References

1.FDA data https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=k050403 

2. Draganov PV, Chauhan S, Wagh MS, Gupte AR, Lin T, Hou W, Forsmark CE. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endos

3. Tyberg A, Raijman I, Siddiqui A, et al. Digital Pancreaticocholangioscopy for Mapping of Pancreaticobiliary Neoplasia: Can We Alter the Surgical Resection Margin? J Clin Gastroenterol. 2019;53(1):71–75.

4. Ramchandani et al. Single Operator Cholangioscopy for the evaluation and diagnosis of Indeterminate biliary strictures – Results from a Large Multinational Registry. DDW 2017.

5. Shah et al. Performance of a full disposable, digital, single-operator cholangiopancreatoiscope. Endoscopy 2017; 49; 651-658.

6. Deprez PH, Duran RG, Moreels T, Furneri G, Demma F, Verbeke L, et al. The economic impact of using single-operator cholangioscopy for the treatment of difficult bile duct stones and diagnosis of indeterminate bile duct strictures Authors. 2018; 109–118.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.​​All images owned by Boston Scientific.​